JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Journal of Clinical Pathology 2006;59:250-254; doi:10.1136/jcp.2005.028589
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Soini, Y
Right arrow Articles by Pääkkö, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soini, Y
Right arrow Articles by Pääkkö, P
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Mesothelioma
*Pleural Disorders

ORIGINAL ARTICLE

Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura

Y Soini1, V Kinnula2, K Kahlos3, P Pääkkö1

1 Department of Pathology, University of Oulu and Oulu University Hospital, Oulu, Finland
2 Department of Medicine, Pulmonary Division, University of Helsinki, Helsinki, Finland
3 Department of Medicine, Pulmonary Division, Oulu University Hospital, Oulu, Finland

Correspondence to:
Dr Y Soini
Department of Pathology, Oulu Central University Hospital, OYS, PO Box 50, 90029 Oulu, Finland; ylermi.soini{at}ppshp.fi Aim: To study the expression of claudins in mesothelioma and metastatic pleural adenocarcinoma.

Methods: Immunohistochemical staining of claudins 1, 2, 3, 4, 5, and 7 was studied in 35 malignant mesotheliomas and the expression compared with 24 cases of pleural metastatic adenocarcinoma. All cases were also immunostained with calretinin.

Results: Claudin 1, 2, 3, 4, 5, and 7 expression was seen in 40%, 80%, 18%, 23%, 14%, and 43% of mesotheliomas, respectively, while the corresponding figures for adenocarcinoma were 100%, 88%, 90%, 100%, 50%, and 92%. Claudins 1, 3, 4, 5, and 7 were significantly less positive in mesothelioma than in metastatic adenocarcinoma, while no difference was observed for claudin 2. Claudins 1, 3, 4, 5, and 7 were also inversely associated with calretinin positivity. Sarcomatoid and biphasic mesothelioma subtypes appeared more negative for these claudins than pure epithelioid subtypes. Claudin expression was not associated with survival of patients with malignant mesotheliomas.

Conclusions: The results show that malignant mesotheliomas have a lower expression of claudins 1, 3, 4, 5, and 7 than adenocarcinomas, and their expression could thus be used as an adjunct in differential diagnosis between the two. The difference was most evident for claudins 3 and 4, which were nearly as good as calretinin in mesothelioma detection. Sarcomatoid and biphasic mesotheliomas showed expression of these claudins only occasionally, which could be due to or contribute to their less epithelial appearance.


Abbreviations: CEA, carcinoembryonic antigen; CK, cytokeratin; EMA, epithelial membrane antigen

Keywords: claudin; mesothelioma; cancer; adhesion; tight junction







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.